Undoubtedly, kidney transplant recipients have a higher mortality due to COVID‐19 disease compared to the general population

Osmanodja, Bilgin; Mayrdorfer, Manuel; Halleck, Fabian; Choi, Mira; Budde, Klemens

doi:10.1111/tri.13881

Cited by 17 publications

(15 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Given that we solely included KTR in our meta‐analyses, we cannot formally compare our results with the risk of dying of COVID‐19 in the general population or non‐KTR patients with CKD. The question remains whether the general population, or a population with specific characteristics (age, comorbidities) would be the correct control population for COVID‐19‐infected KTR 32 . Finally, our risk of bias analysis suggests that common methodological shortcomings are identified in the included studies and we stress the importance of adjusting effect estimates for important confounders and an adequate follow‐up with good retention.…”

Section: Discussionmentioning

confidence: 89%

A systematic review and meta-analysis of COVID-19 in kidney transplant recipients: Lessons to be learned

Kremer

Pieters

Verhaar

et al. 2021

American Journal of Transplantation

View full text Add to dashboard Cite

Kidney transplant recipients (KTR) may be at increased risk of adverse COVID‐19 outcomes, due to prevalent comorbidities and immunosuppressed status. Given the global differences in COVID‐19 policies and treatments, a robust assessment of all evidence is necessary to evaluate the clinical course of COVID‐19 in KTR. Studies on mortality and acute kidney injury (AKI) in KTR in the World Health Organization COVID‐19 database were systematically reviewed. We selected studies published between March 2020 and January 18th 2021, including at least five KTR with COVID‐19. Random‐effects meta‐analyses were performed to calculate overall proportions, including 95% confidence intervals (95% CI). Subgroup analyses were performed on time of submission, geographical region, sex, age, time after transplantation, comorbidities, and treatments. We included 74 studies with 5559 KTR with COVID‐19 (64.0% males, mean age 58.2 years, mean 73 months after transplantation) in total. The risk of mortality, 23% (95% CI: 21%–27%), and AKI, 50% (95% CI: 44%–56%), is high among KTR with COVID‐19, regardless of sex, age and comorbidities, underlining the call to accelerate vaccination programs for KTR. Given the suboptimal reporting across the identified studies, we urge researchers to consistently report anthropometrics, kidney function at baseline and discharge, (changes in) immunosuppressive therapy, AKI, and renal outcome among KTR.

show abstract

Section: Discussionmentioning

confidence: 89%

A systematic review and meta-analysis of COVID-19 in kidney transplant recipients: Lessons to be learned

Kremer

Pieters

Verhaar

et al. 2021

American Journal of Transplantation

View full text Add to dashboard Cite

show abstract

“…Kidney transplant recipients were at a higher risk of death from COVID-19-related complications compared with the general population ( 19 ). However, data from an Italian center, collected during the early phase of the pandemic, indicated that all kidney transplant recipients with concomitant COVID-19 survived when immunosuppression was maintained (or switched from mycophenolate mofetil to high-dose steroids) ( 20 ).…”

Section: Treating Covid-19 Infection In Kidney Transplant Recipientsmentioning

confidence: 99%

Impact of COVID-19 on Global Kidney Transplantation Service Delivery: Interim Report

Papalois¹,

Kotton

Budde

et al. 2022

Transpl Int

Self Cite

View full text Add to dashboard Cite

This article gives a personal, historical, account of the impact of the COVID-19 pandemic on transplantation services. The content is based on discussions held at two webinars in November 2020, at which kidney transplantation experts from prestigious institutions in Europe and the United States reflected on how the pandemic affected working practices. The group discussed adaptations to clinical care (i.e., ceasing, maintaining and re-starting kidney transplantations, and cytomegalovirus infection management) across the early course of the pandemic. Discussants were re-contacted in October 2021 and asked to comment on how transplantation services had evolved, given the widespread access to COVID-19 testing and the roll-out of vaccination and booster programs. By October 2021, near-normal life and service delivery was resuming, despite substantial ongoing cases of COVID-19 infection. However, transplant recipients remained at heightened risk of COVID-19 infection despite vaccination, given their limited response to mRNA vaccines and booster dosing: further risk-reduction strategies required exploration. This article provides a contemporaneous account of these different phases of the pandemic from the transplant clinician’s perspective, and provides constructive suggestions for clinical practice and research.

show abstract

“…Overall mortality in hospitalized CKD patients was 26% ( 12 ). While many CKD patients are of advanced age with age being another major risk factor for poor outcomes, kidney transplantation constitutes a further risk factor for SARS-CoV-2 infected individuals ( 14 , 15 ). Besides immunosuppression, graft function was inversely correlated with COVID-19 disease severity ( 16 ).…”

Section: Introductionmentioning

confidence: 99%

Initial Experience With SARS-CoV-2-Neutralizing Monoclonal Antibodies in Kidney or Combined Kidney-Pancreas Transplant Recipients

Bachmann

Budde

Suttorp³

et al. 2022

Transpl Int

Self Cite

View full text Add to dashboard Cite

show abstract

Undoubtedly, kidney transplant recipients have a higher mortality due to COVID‐19 disease compared to the general population

Cited by 17 publications

References 10 publications

A systematic review and meta-analysis of COVID-19 in kidney transplant recipients: Lessons to be learned

A systematic review and meta-analysis of COVID-19 in kidney transplant recipients: Lessons to be learned

Impact of COVID-19 on Global Kidney Transplantation Service Delivery: Interim Report

Initial Experience With SARS-CoV-2-Neutralizing Monoclonal Antibodies in Kidney or Combined Kidney-Pancreas Transplant Recipients

Contact Info

Product

Resources

About